TNS3 and cancer: SMTIN-P01 was design by introducing a mitochondria-targeting triphenylphosphine (TPP) moiety into PU-H71, which achieved accumulation of the molecule in mitochondria and selectively impaired the chaperone activity of TRAP-1.471 Besides, there are two TRAP-1 selective inhibitors containing TPP moiety, including gamitrinib-TPP and 6BrCaQ-TPP.472 Gamitrinib-TPP is another conjugate of 17-AAG and TPP moiety and entered into clinical trial of advanced cancers, which proved the feasibility of design TRAP-1 selective inhibitors using mitochondria-targeting moieties.473,474